Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule
News Apr 28, 2009
Santaris Pharma has announced the completion of the delivery of six cancer target drug candidates to their collaboration partner Enzon Pharmaceuticals. All six drug candidates have been designed, synthesized and selected in collaboration with Enzon, within 24 months of commencing the collaboration.
"Our collaboration with Enzon Pharmaceuticals has been very productive and goal oriented enabling both companies to benefit optimally from our ability to rationally design, discover and select potent and safe RNA targeted drugs within a short time span," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer.
Santaris Pharma and Enzon Pharmaceuticals signed their agreement in 2006. As part of the agreement Santaris Pharma retains the lucrative commercial rights to the drugs within Europe.
The agreement included two LNA based RNA inhibitors at the pre-clinical stage, EZN2968 against HIF-1Î±, and EZN3042 against Survivin, both of which are currently in Phase I studies conducted by Enzon, and the development of six additional cancer target drugs selected by Enzon which are in various stages of preclinical development.
"We are encouraged by the data generated by the first two lead candidates," said Dr. Ivan Horak, Executive Vice President of Research, Development and Chief Scientific Officer, Enzon Pharmaceuticals. "In addition, I'm pleased to see the continued validation of the Locked Nucleic Acid (LNA) technology as we continue to evaluate the additional targets in preclinical programs."
Stereochemistry is a science of reflection. Two chemical molecules with the same composition and structure, but with one as the mirror image of the other, can produce wildly varying effects. But University of Utah chemist Matt Sigman has been developing a way to get a better grasp on this tricky field of chemistry.READ MORE